Effects of COVID-19 Pandemic on Metabolic Status and Psychological Correlates of a Cohort of Italian NAFLD Outpatients.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
16 Mar 2023
Historique:
received: 17 02 2023
revised: 13 03 2023
accepted: 15 03 2023
medline: 30 3 2023
entrez: 29 3 2023
pubmed: 30 3 2023
Statut: epublish

Résumé

Non-alcoholic fatty liver disease (NAFLD) is a potentially progressive condition characterized by the presence of fat in more than 5% of hepatocytes, representing the hepatic expression of metabolic syndrome (MetS). A reduction of at least 5-7% in initial body weight improves the metabolic profile underlying NAFLD. The aim of our study was to evaluate the effects of the COVID-19 lockdown on a cohort of non-advanced NAFLD Italian outpatients. We identified 43 patients with 3 available time point visits in our center: first visit (T0) when behavioral indications aimed at controlling MetS were provided, a pre-COVID visit (T1) and a post-COVID visit (T2). During the lockdown, an online compilation of validated psychological tests (SRQ-20, EQ5D, SF-12 and STAI) and a specifically formulated questionnaire for NAFLD was presented to our cohort and completed by 14 consenting patients. Patients who had lost more than 5% of the initial weight at T1 (9 subjects, 21%) maintained the results even at T2, with an overall reduction in BMI and liver stiffness; patients who had not lost the desired weight at T1 (34 subjects, 79%) displayed a further increase in BMI and visceral adiposity at T2. Of interest is that patients in the latter group reported signs of psychological suffering. Our data demonstrated that the setting of good counseling was effective in controlling the metabolic disorder underlying NAFLD in our cohort of outpatients. Given the need for patients to play an active role in the behavioral therapy for NAFLD, we advocate that a multidisciplinary approach be adopted, including a psychological support to obtain the best results over time.

Identifiants

pubmed: 36986175
pii: nu15061445
doi: 10.3390/nu15061445
pmc: PMC10052521
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Hepatol. 2015 Nov;63(5):1229-37
pubmed: 26385766
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
Dig Liver Dis. 2019 Dec;51(12):1698-1705
pubmed: 31281067
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
J Prev Med Hyg. 2022 Oct 17;63(2 Suppl 3):E36-E43
pubmed: 36479477
Gen Hosp Psychiatry. 2011 May-Jun;33(3):232-7
pubmed: 21601719
BMC Public Health. 2021 Apr 23;21(1):786
pubmed: 33892688
JAMA. 1999 Nov 3;282(17):1659-64
pubmed: 10553793
BMC Med. 2020 Oct 1;18(1):261
pubmed: 32998725
J Hepatol. 2017 Oct;67(4):829-846
pubmed: 28545937
Proc Nutr Soc. 2017 Nov;76(4):427-436
pubmed: 28942748
Diabet Med. 2018 Mar;35(3):368-375
pubmed: 29247558
Hepatology. 2015 Apr;61(4):1205-15
pubmed: 25271091
Clin Nutr. 2022 Sep;41(9):1913-1931
pubmed: 35947894
Nutrients. 2022 Jun 16;14(12):
pubmed: 35745223
J Hepatol. 2019 Mar;70(3):545-547
pubmed: 30685123
Pharmacol Rep. 2015 Jun;67(3):569-80
pubmed: 25933971
J Clin Ultrasound. 2013 Jan;41(1):18-25
pubmed: 22997020
Frontline Gastroenterol. 2015 Jan;6(1):44-51
pubmed: 25580206
J Hepatol. 2018 Dec;69(6):1349-1356
pubmed: 30142427
Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5
pubmed: 25865049
Metabolism. 2017 Mar;68:119-132
pubmed: 28183444
Br J Nutr. 2022 Jan 28;127(2):298-317
pubmed: 33706844
Nutrients. 2020 Jul 19;12(7):
pubmed: 32707724
Eur J Clin Invest. 2021 Jul;51(7):e13597
pubmed: 34032283
Liver Int. 2013 Aug;33(7):1062-70
pubmed: 23560860
Nutrients. 2021 Mar 26;13(4):
pubmed: 33810256
Liver Int. 2015 Mar;35(3):936-43
pubmed: 24521540
J Hepatol. 2013 Jul;59(1):138-43
pubmed: 23485520

Auteurs

Silvia Ferri (S)

Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

Bernardo Stefanini (B)

Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.

Marta Minguzzi (M)

Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.

Simona Leoni (S)

Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

Roberta Capelli (R)

Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.

Alice Secomandi (A)

Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.

Rusi Chen (R)

Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.

Chiara Abbati (C)

Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.

Ernestina Santangeli (E)

Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.

Katia Mattarozzi (K)

Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.

Piscaglia Fabio (P)

Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH